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See Article, pages 696–700Viral co-infections with HBV or HIV are well known to aggravate
the evolution of chronic hepatitis C (CHC). With respect to HBV,
although the impact of overt infection has been well character-
ized, the role of occult HBV infection (OBI) on the outcome of
CHC remains elusive [1,2]. OBI are mainly deﬁned by the persis-
tence of HBV genome in the liver of individuals testing negative
for HBsAg [1]. The mechanisms by which the persistence of the
viral genome is not associated with a full expression of viral anti-
gens and viral replication are still partially known [3]. The patho-
biological and clinical consequences of HBV genome persistence
as an OBI, whether as a mono-infection or as a co-infection with
HCV, include an increased severity of liver disease and an
increased risk of HCC [4]. However, most of the published studies
were cross-sectional and were therefore subjected to potential
bias in patient selection.
OBI is highly prevalent in patients with CHC, at least in areas
of high HBV prevalence. Whether OBI might negatively inﬂuence
CHC clinical outcome, favoring its progression toward cirrhosis,
has been largely debated for many years. Controversies remains
on the possible prooncogenic role exerted by OBI, particularly
in CHC patients [5]. A recent meta-analysis suggested that OBI
increases the risk of hepatocellular carcinoma (HCC) develop-
ment in both HCV and non-HCV infected patients [6], but other
studies performed in North America did not ﬁnd such an associ-
ation [7].
One main reason for the discussion of the possible contribu-
tion of OBI to a more severe evolution of CHC is the lack of longi-
tudinal studies evaluating the clinical outcome of HCV patients
according to the status of OBI during a sufﬁcient period of obser-
vation to allow clinical events to occur.
In this paper, Squadrito et al. [8] have performed a long
awaited observational cohort study evaluating the clinical evolu-
tion of CHC patients according to their OBI status. From 1991 to
2000, 326 HBsAg negative CHC patients were tested for OBI by
the analysis of HBV genome by PCR in liver biopsy samples. A
total of 128/326 cases (39.2%) tested OBI positive and 198/326
(60.8%) OBI negative. Ninety-four of 326 patients (37 OBI posi-
tive, 57 OBI negative) were followed-up for a median time ofJournal of Hepatology 20
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the follow-up, 79/94 patients underwent anti-HCV treatments
and 26 achieved a sustained virological response that occurred
independently of their OBI status. Eighteen patients (13/37 OBI
positive, 5/57 OBI negative, p <0.01) developed HCC. Among the
76 non-HCC individuals, 15 subjects (8/24 OBI positive, 7/52
OBI negative, p <0.05) developed advanced forms of cirrhosis.
Eighteen patients died during the follow-up and 2 underwent
liver transplantation. OBI positive individuals had a cumulative
survival rate signiﬁcantly shorter than OBI negative individuals
(p = 0.003). Liver related deaths were more frequently found in
OBI positive than OBI negative patients (12/37 OBI positive vs.
6/57 OBI negative patients, respectively, p <0.01). Finally, non-
response to anti-HCV therapy was signiﬁcantly associated with
lower survival (p = 0.02). Therefore, the authors concluded that
among CHC patients, OBI co-infected individuals are at high risk
of progression toward cirrhosis, HCC development, and lower
survival.
Although this study was not designed as a true prospective
study, it is an important evaluation over time of a cohort of unse-
lected HCV patients who underwent a liver biopsy and tested for
OBI in a single liver unit in Sicily in the 90s. This is the ﬁrst lon-
gitudinal cohort addressing this question. The authors tried to
carefully rule out an inﬂuence of alcohol consumption and ciga-
rette smoking as potential cofactors inﬂuencing the outcome of
CHC [9]. They also considered the potential role of liver steatosis
on the analysis of liver histology at baseline to assess the possible
dependence of the events occurring in this HCV cohort, but did
not show any correlation with a severe outcome of the disease.
It is noteworthy that in OBI patients who developed HCC or
severe worsening of liver disease, only a minority had cirrhosis
at the time of biopsy (4 among HCC patients, 2 being OBI positive,
and 6 among patients with progressive liver disease, 3 being OBI
positive), suggesting an important role of occult HBV in the pro-
gression of liver disease and occurrence of clinical events.
Unfortunately, data evaluating the rate of progression of the
liver disease are lacking since a second liver biopsy was per-
formed only in a small number of cases during follow-up, when
it was clinically relevant, while non-invasive approaches assess-
ing ﬁbrosis progression, such as ﬁbroscan, were not available
for the majority of patients. In that respect, it would be interest-
ing to study, in a retrospective manner, blood markers of liver
ﬁbrosis on stored serum samples.13 vol. 59 j 646–647 Open access under CC BY-NC-ND license.
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This important clinical study provides new information to our
knowledge of the potentiating role of OBI in the evolution of liver
disease in the context of CHC. This opens new questions regard-
ing the pathobiology of these co-infections. Up to now, there was
no suitable cell culture system to analyze a true co-infection with
both HCV and HBV. Primary hepatocytes or HepaRG cells which
are susceptible to HBV infection do not yet support robust levels
of HCV replication. A HuH7.5 cell line stably transfected with the
HBV genome was transfected with HCV replicons or infected with
HCVcc, but results did not show direct viral interference [10].
With the discovery of sodium taurocholate cotransporting poly-
peptide (NTCP) as a receptor for HBV infection, it will now be pos-
sible to study the pathogenesis of true co-infections in this
transformed hepatoma cell line [11,12]. New technological devel-
opments will be necessary to obtain non-transformed hepatocyte
cell culture systems susceptible to both viruses to study the
impact of their interactions on hepatocyte biology at the molec-
ular level; in this respect, the recently published model based
on human induced pluripotent stem cells (iPSCs) offers the ability
to produce host-speciﬁc differentiated cells that might be suscep-
tible to infection by both viruses [13]. On a clinical point of view,
it would be important to obtain independent conﬁrmation of
these results in other cohorts of patients from different regions
of the world, where HBV infection is highly prevalent. Indeed, if
conﬁrmed, this would have major clinical implications in terms
of diagnosis of OBI, which would then require the development
of standardized assays. Another important impact would be on
the management of patients who would need more aggressive
treatment intervention. However, there is currently no proven
beneﬁcial effect of anti-HBV therapy on OBI itself. Interestingly,
the ﬁnding that patients who cleared HCV infection upon anti-
HCV therapy had a better clinical outcome is reassuring.
In conclusion, this is an important longitudinal clinical study
showing the role of occult HBV infection in the progression of
chronic hepatitis C in an Italian cohort of patients. Further studies
are warranted to better understand the molecular basis of liver
pathogenesis in the setting of this viral co-infection and to better
deﬁne the clinical management of these patients.Conﬂict of interest
The author declared that he does not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.Journal of Hepatology 201References
[1] Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al.
Statements from the Taormina expert meeting on occult hepatitis B virus
infection. J Hepatol 2008;49:652–657, [Congresses].
[2] Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis
2002;2:479–486, [Research Support, U.S. Gov’t, P.H.S. Review].
[3] Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, et al.
Molecular and functional analysis of occult hepatitis B virus isolates from
patients with hepatocellular carcinoma. Hepatology 2007;45:277–285,
[Research Support, Non-U.S. Gov’t].
[4] Squadrito G, Pollicino T, Cacciola I, Caccamo G, Villari D, La Masa T, et al.
Occult hepatitis B virus infection is associated with the development of
hepatocellular carcinoma in chronic hepatitis C patients. Cancer
2006;106:1326–1330, [Comparative Study Research Support, Non-U.S.
Gov’t].
[5] Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxi A, et al.
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult
HBV infection. Gastroenterology 2004;126:102–110.
[6] Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z. Association between occult
hepatitis B infection and the risk of hepatocellular carcinoma: a meta-
analysis. Liver Int 2012;32:231–240, [Meta-Analysis Research Support, Non-
U.S. Gov’t].
[7] Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR. Occult
and previous hepatitis B virus infection are not associated with hepatocel-
lular carcinoma in United States patients with chronic hepatitis C. Hepatol-
ogy 2011;54:434–442, [Comparative Study Randomized Controlled Trial
Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t].
[8] Squadrito G et al. Impact of occult hepatitis B virus infection on the outcome
of chronic hepatitis C. J Hepatol 2013;59:696–700.
[9] Mallat A, Hezode C, Lotersztajn S. Environmental factors as disease
accelerators during chronic hepatitis C. J Hepatol 2008;48:657–665,
[Research Support, Non-U.S. Gov’t Review].
[10] Bellecave P, Gouttenoire J, Gajer M, Brass V, Koutsoudakis G, Blum HE, et al.
Hepatitis B and C virus coinfection: a novel model system reveals the
absence of direct viral interference. Hepatology 2009;50:46–55, [Research
Support, Non-U.S. Gov’t].
[11] Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate
cotransporting polypeptide is a functional receptor for human hepatitis B
and D virus. Elife 2012;1:e00049.
[12] Seeger C, Mason WS. Sodium-dependent taurocholic cotransporting poly-
peptide: a candidate receptor for human hepatitis B virus. Gut
2013;62:1093–1095.
[13] Schwartz RE, Trehan K, Andrus L, Sheahan TP, Ploss A, Duncan SA, et al.
Modeling hepatitis C virus infection using human induced pluripotent stem
cells. Proc Natl Acad Sci U S A 2012;109:2544–2548, [Research Support,
N.I.H., Extramural Research Support, Non-U.S. Gov’t].3 vol. 59 j 646–647 647
